153 related articles for article (PubMed ID: 18368291)
21. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Yun T; Han JY; Lee JS; Choi HL; Kim HY; Nam BH; Kim HT
BMC Cancer; 2011 Sep; 11():385. PubMed ID: 21888637
[TBL] [Abstract][Full Text] [Related]
23. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
[TBL] [Abstract][Full Text] [Related]
24. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
[TBL] [Abstract][Full Text] [Related]
25. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
[TBL] [Abstract][Full Text] [Related]
27. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus.
Allen SM; Duffy JP; Walker SJ; Darnton SJ; Cullen MH; Matthews HR
Clin Oncol (R Coll Radiol); 1994; 6(2):91-5. PubMed ID: 8018579
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Zhang F; Wang Y; Wang ZQ; Sun P; Wang DS; Jiang YX; Zhang DS; Wang FH; Xu RH; Li YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868295
[TBL] [Abstract][Full Text] [Related]
32. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.
Hiramoto S; Kato K; Shoji H; Okita N; Takashima A; Honma Y; Iwasa S; Hamaguchi T; Yamada Y; Shimada Y; Boku N
Int J Clin Oncol; 2018 Jun; 23(3):466-472. PubMed ID: 29353337
[TBL] [Abstract][Full Text] [Related]
34. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
[TBL] [Abstract][Full Text] [Related]
35. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
36. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
38. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Glisson BS; Murphy BA; Frenette G; Khuri FR; Forastiere AA
J Clin Oncol; 2002 Mar; 20(6):1593-9. PubMed ID: 11896109
[TBL] [Abstract][Full Text] [Related]
39. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
[TBL] [Abstract][Full Text] [Related]
40. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
